Floatz logo

[225Ac]Ac-AKY-1189

Colorectal Adenocarcinoma

Aktis Oncology, Inc.radiopharmaceuticalPhase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

66 Active assets in the Colorectal Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Regorafenib
City of Hope Medical Center
Phase 2BB
Trifluridine
Centre Hospitalier Universitaire Dijon
Phase 3BB
Botensilimab
City of Hope Medical Center
Phase 2BB
Balstilimab
City of Hope Medical Center
Phase 2BB
Eloxatin
Pfizer
Phase 3BB

View all 50 →

Same molecule, other indications

[225Ac]Ac-AKY-1189 is also rated in:

hormone receptor-positive breast cancerDormant
CC
Indicative ·
43 / 100
View asset →
cervical adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →
bladder transitional cell carcinomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →